Your browser doesn't support javascript.
loading
Emergency department-initiated buprenorphine protocols: A national evaluation.
Guo, Clara Z; D'Onofrio, Gail; Fiellin, David A; Edelman, E Jennifer; Hawk, Kathryn; Herring, Andrew; McCormack, Ryan; Perrone, Jeanmarie; Cowan, Ethan.
Afiliação
  • Guo CZ; Yale University School of Medicine New Haven Connecticut USA.
  • D'Onofrio G; Department of Emergency Medicine Yale University School of Medicine New Haven Connecticut USA.
  • Fiellin DA; Department of Internal Medicine Yale University School of Medicine New Haven Connecticut USA.
  • Edelman EJ; Department of Internal Medicine Yale University School of Medicine New Haven Connecticut USA.
  • Hawk K; Department of Emergency Medicine Yale University School of Medicine New Haven Connecticut USA.
  • Herring A; Department of Emergency Medicine Highland Hospital - Alameda Health System University of California San Francisco California USA.
  • McCormack R; Department of Emergency Medicine New York University School of Medicine New York New York USA.
  • Perrone J; Department of Emergency Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA.
  • Cowan E; Department of Emergency Medicine Icahn School of Medicine at Mount Sinai New York New York USA.
J Am Coll Emerg Physicians Open ; 2(6): e12606, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34877567
ABSTRACT

OBJECTIVE:

Emergency department-initiated buprenorphine (BUP) for opioid use disorder is an evidence-based practice, but limited data exist on BUP initiation practices in real-world settings. We sought to characterize protocols for BUP initiation among a geographically diverse sample of emergency departments (EDs).

METHODS:

In December 2020, we reviewed prestudy clinical BUP initiation protocols from all EDs participating in CTN0099 Emergency Department-INitiated bupreNOrphine VAlidaTION (ED-INNOVATION). We abstracted information on processes for identification of treatment-eligible patients, BUP administration, and discharge care.

RESULTS:

All participating ED-INNOVATION sites across 22 states submitted protocols; 31 protocols were analyzed. Identification of treatment-eligible patients Most EDs 22 (71%) relied on clinician judgment to determine appropriateness of BUP treatment with only 7 (23%) requiring decision support tools or diagnosis checklists. Before BUP initiation, 27 (87%) protocols required a documented Clinical Opiate Withdrawal Scale (COWS) score; 4 (13%) required a clinical diagnosis of withdrawal with optional COWS score. Twenty-seven (87%) recommended a minimum COWS score of 8 for ED-initiated BUP. BUP administration Initial BUP dose ranged from 2-16 mg (mode = 4). For continued withdrawal symptoms, 27 (87%) protocols recommended an interval of 30-60 minutes between first and second BUP dose. Total BUP dose in the ED ranged from 8 to 32 mg. Discharge care Twenty-eight (90%) protocols recommended a BUP prescription (mode 16 mg daily) at discharge. Naloxone prescription and/or provision was suggested in 23 (74%) protocols.

CONCLUSIONS:

In this geographically diverse sample of EDs, protocols for ED-initiated BUP differed between sites. Future work should evaluate the association between this variation and patient outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article